US Patent

US12138257 — Antimicrobial compositions

Formulation · Assigned to Melinta Subsidiary Corp · Expires 2032-05-01 · 6y remaining

Vulnerability score 61/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects antimicrobial compositions, specifically quinolone carboxylic acid derivatives, for intravenous administration.

USPTO Abstract

The present invention relates to antimicrobial compositions and more specifically compositions of quinolone carboxylic acid derivatives. These compositions have improved solubility, stability, and tolerability. These compositions are useful for intravenous administration for treating, preventing, or reducing the risk of infection.

Drugs covered by this patent

delafloxacin-meglumine (DELAFLOXACIN MEGLUMINE)

Patent Metadata

Patent number: US12138257
Jurisdiction: US
Classification: Formulation
Expires: 2032-05-01
Drug substance claim: No
Drug product claim: Yes
Assignee: Melinta Subsidiary Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.